cdk4 6 inhibitors Search Results


abemaciclib  (TargetMol)
99
TargetMol abemaciclib
Combined treatment of antiestrogen-resistant ER+ BC with ASO targeting circESR1 and CDK4/6i. (A-B) The relative expression of circESR1 , ESR1 mRNA and ESR1 pre-mRNA in MCF-7 or T-47D parental and tamoxifen resistant (TamR) cells analyzed by qRT-PCR. (C) Immunoblot assessed the expression of HNRNPAB, SP1, CDK1, CDK6 and ERα proteins in MCF-7 parental and TamR cells. (D-E) Cell viability in MCF-7 parental and TamR cells bearing control ASO or ASO targeting circESR1 determined by MTT assay. (F) MCF-7 and T-47D parental and TamR cells were transiently transfected with control ASO or ASO targeting circESR1 , and were treated with different concentration gradients of CDK4/6i for 48 h. The drug killing curve of the cells was detected by MTT assay. (G) Foci formation to detect the effects of combining <t>abemaciclib,</t> palbociclib, and ribociclib on MCF-7 TamR cells transiently transfected with control ASO or ASO targeting circESR1 . (H) Immunoblot assessment of HNRNPAB, CDK1 and CDK6 proteins in MCF-7 TamR cells, which were transiently transfected with control ASO or ASO targeting circESR1 and treated with palbociclib for 48 h. (I-J) Changes in tumor growth volume in xenograft mouse models. Injected with 1×10 6 MCF-7 TamR cells under the second pair of fat pads on both sides of the mammary glands of female BALB/c nude mice (n=5/group). Tamoxifen (20 μg per dose) dissolved in 125 μL corn oil was injected every 3 days i.p. When the xenograft volume reached approximately 200 mm 3 , tumor-bearing mice were randomized and received intratumoral injection of negative control or ASO- circESR1 (5nM per dose, every 3 days) in the presence or absence of palbociclib (100mg/kg/week i.g.). (K) Hematoxylin and eosin (H&E) staining, ISH for circESR1 and IHC for Ki-67, HNRNPAB, SP1, CDK1 and CDK6 in tumor sections derived from (I). Scale bars, 20 μm. Data was shown as mean ± S.D. from three independent experiments. Unpaired two-tailed Student's t test (A-B) and two-way ANOVA test (D-E, J). ***, P < 0.001; ****, P < 0.0001.
Abemaciclib, supplied by TargetMol, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/abemaciclib/product/TargetMol
Average 99 stars, based on 1 article reviews
abemaciclib - by Bioz Stars, 2026-03
99/100 stars
  Buy from Supplier
cdk4 6 inhibitor iv  (Santa Cruz Biotechnology)
86
Santa Cruz Biotechnology cdk4 6 inhibitor iv
Combined treatment of antiestrogen-resistant ER+ BC with ASO targeting circESR1 and CDK4/6i. (A-B) The relative expression of circESR1 , ESR1 mRNA and ESR1 pre-mRNA in MCF-7 or T-47D parental and tamoxifen resistant (TamR) cells analyzed by qRT-PCR. (C) Immunoblot assessed the expression of HNRNPAB, SP1, CDK1, CDK6 and ERα proteins in MCF-7 parental and TamR cells. (D-E) Cell viability in MCF-7 parental and TamR cells bearing control ASO or ASO targeting circESR1 determined by MTT assay. (F) MCF-7 and T-47D parental and TamR cells were transiently transfected with control ASO or ASO targeting circESR1 , and were treated with different concentration gradients of CDK4/6i for 48 h. The drug killing curve of the cells was detected by MTT assay. (G) Foci formation to detect the effects of combining <t>abemaciclib,</t> palbociclib, and ribociclib on MCF-7 TamR cells transiently transfected with control ASO or ASO targeting circESR1 . (H) Immunoblot assessment of HNRNPAB, CDK1 and CDK6 proteins in MCF-7 TamR cells, which were transiently transfected with control ASO or ASO targeting circESR1 and treated with palbociclib for 48 h. (I-J) Changes in tumor growth volume in xenograft mouse models. Injected with 1×10 6 MCF-7 TamR cells under the second pair of fat pads on both sides of the mammary glands of female BALB/c nude mice (n=5/group). Tamoxifen (20 μg per dose) dissolved in 125 μL corn oil was injected every 3 days i.p. When the xenograft volume reached approximately 200 mm 3 , tumor-bearing mice were randomized and received intratumoral injection of negative control or ASO- circESR1 (5nM per dose, every 3 days) in the presence or absence of palbociclib (100mg/kg/week i.g.). (K) Hematoxylin and eosin (H&E) staining, ISH for circESR1 and IHC for Ki-67, HNRNPAB, SP1, CDK1 and CDK6 in tumor sections derived from (I). Scale bars, 20 μm. Data was shown as mean ± S.D. from three independent experiments. Unpaired two-tailed Student's t test (A-B) and two-way ANOVA test (D-E, J). ***, P < 0.001; ****, P < 0.0001.
Cdk4 6 Inhibitor Iv, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cdk4 6 inhibitor iv/product/Santa Cruz Biotechnology
Average 86 stars, based on 1 article reviews
cdk4 6 inhibitor iv - by Bioz Stars, 2026-03
86/100 stars
  Buy from Supplier
cdk4/6 inhibitors 2′-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)amino)-7′,8′-dihydro-6′h-spiro[cyclohexane-1,9′-pyrazino[1′,2′:1,5]pyrrolo[2,3-d]pyrimidin]-6′-one  (G1 Therapeutics)
90
G1 Therapeutics cdk4/6 inhibitors 2′-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)amino)-7′,8′-dihydro-6′h-spiro[cyclohexane-1,9′-pyrazino[1′,2′:1,5]pyrrolo[2,3-d]pyrimidin]-6′-one
Combined treatment of antiestrogen-resistant ER+ BC with ASO targeting circESR1 and CDK4/6i. (A-B) The relative expression of circESR1 , ESR1 mRNA and ESR1 pre-mRNA in MCF-7 or T-47D parental and tamoxifen resistant (TamR) cells analyzed by qRT-PCR. (C) Immunoblot assessed the expression of HNRNPAB, SP1, CDK1, CDK6 and ERα proteins in MCF-7 parental and TamR cells. (D-E) Cell viability in MCF-7 parental and TamR cells bearing control ASO or ASO targeting circESR1 determined by MTT assay. (F) MCF-7 and T-47D parental and TamR cells were transiently transfected with control ASO or ASO targeting circESR1 , and were treated with different concentration gradients of CDK4/6i for 48 h. The drug killing curve of the cells was detected by MTT assay. (G) Foci formation to detect the effects of combining <t>abemaciclib,</t> palbociclib, and ribociclib on MCF-7 TamR cells transiently transfected with control ASO or ASO targeting circESR1 . (H) Immunoblot assessment of HNRNPAB, CDK1 and CDK6 proteins in MCF-7 TamR cells, which were transiently transfected with control ASO or ASO targeting circESR1 and treated with palbociclib for 48 h. (I-J) Changes in tumor growth volume in xenograft mouse models. Injected with 1×10 6 MCF-7 TamR cells under the second pair of fat pads on both sides of the mammary glands of female BALB/c nude mice (n=5/group). Tamoxifen (20 μg per dose) dissolved in 125 μL corn oil was injected every 3 days i.p. When the xenograft volume reached approximately 200 mm 3 , tumor-bearing mice were randomized and received intratumoral injection of negative control or ASO- circESR1 (5nM per dose, every 3 days) in the presence or absence of palbociclib (100mg/kg/week i.g.). (K) Hematoxylin and eosin (H&E) staining, ISH for circESR1 and IHC for Ki-67, HNRNPAB, SP1, CDK1 and CDK6 in tumor sections derived from (I). Scale bars, 20 μm. Data was shown as mean ± S.D. from three independent experiments. Unpaired two-tailed Student's t test (A-B) and two-way ANOVA test (D-E, J). ***, P < 0.001; ****, P < 0.0001.
Cdk4/6 Inhibitors 2′ ((5 (4 Methylpiperazin 1 Yl)Pyridin 2 Yl)Amino) 7′,8′ Dihydro 6′H Spiro[Cyclohexane 1,9′ Pyrazino[1′,2′:1,5]Pyrrolo[2,3 D]Pyrimidin] 6′ One, supplied by G1 Therapeutics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cdk4/6 inhibitors 2′-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)amino)-7′,8′-dihydro-6′h-spiro[cyclohexane-1,9′-pyrazino[1′,2′:1,5]pyrrolo[2,3-d]pyrimidin]-6′-one/product/G1 Therapeutics
Average 90 stars, based on 1 article reviews
cdk4/6 inhibitors 2′-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)amino)-7′,8′-dihydro-6′h-spiro[cyclohexane-1,9′-pyrazino[1′,2′:1,5]pyrrolo[2,3-d]pyrimidin]-6′-one - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
cdk4/6 inhibitors  (Bioscientifica Ltd)
90
Bioscientifica Ltd cdk4/6 inhibitors
Combined treatment of antiestrogen-resistant ER+ BC with ASO targeting circESR1 and CDK4/6i. (A-B) The relative expression of circESR1 , ESR1 mRNA and ESR1 pre-mRNA in MCF-7 or T-47D parental and tamoxifen resistant (TamR) cells analyzed by qRT-PCR. (C) Immunoblot assessed the expression of HNRNPAB, SP1, CDK1, CDK6 and ERα proteins in MCF-7 parental and TamR cells. (D-E) Cell viability in MCF-7 parental and TamR cells bearing control ASO or ASO targeting circESR1 determined by MTT assay. (F) MCF-7 and T-47D parental and TamR cells were transiently transfected with control ASO or ASO targeting circESR1 , and were treated with different concentration gradients of CDK4/6i for 48 h. The drug killing curve of the cells was detected by MTT assay. (G) Foci formation to detect the effects of combining <t>abemaciclib,</t> palbociclib, and ribociclib on MCF-7 TamR cells transiently transfected with control ASO or ASO targeting circESR1 . (H) Immunoblot assessment of HNRNPAB, CDK1 and CDK6 proteins in MCF-7 TamR cells, which were transiently transfected with control ASO or ASO targeting circESR1 and treated with palbociclib for 48 h. (I-J) Changes in tumor growth volume in xenograft mouse models. Injected with 1×10 6 MCF-7 TamR cells under the second pair of fat pads on both sides of the mammary glands of female BALB/c nude mice (n=5/group). Tamoxifen (20 μg per dose) dissolved in 125 μL corn oil was injected every 3 days i.p. When the xenograft volume reached approximately 200 mm 3 , tumor-bearing mice were randomized and received intratumoral injection of negative control or ASO- circESR1 (5nM per dose, every 3 days) in the presence or absence of palbociclib (100mg/kg/week i.g.). (K) Hematoxylin and eosin (H&E) staining, ISH for circESR1 and IHC for Ki-67, HNRNPAB, SP1, CDK1 and CDK6 in tumor sections derived from (I). Scale bars, 20 μm. Data was shown as mean ± S.D. from three independent experiments. Unpaired two-tailed Student's t test (A-B) and two-way ANOVA test (D-E, J). ***, P < 0.001; ****, P < 0.0001.
Cdk4/6 Inhibitors, supplied by Bioscientifica Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cdk4/6 inhibitors/product/Bioscientifica Ltd
Average 90 stars, based on 1 article reviews
cdk4/6 inhibitors - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
cdk4/6 inhibitors in combination with xvir-n-31  (XVir Therapeutics GmbH)
90
XVir Therapeutics GmbH cdk4/6 inhibitors in combination with xvir-n-31
Combined treatment of antiestrogen-resistant ER+ BC with ASO targeting circESR1 and CDK4/6i. (A-B) The relative expression of circESR1 , ESR1 mRNA and ESR1 pre-mRNA in MCF-7 or T-47D parental and tamoxifen resistant (TamR) cells analyzed by qRT-PCR. (C) Immunoblot assessed the expression of HNRNPAB, SP1, CDK1, CDK6 and ERα proteins in MCF-7 parental and TamR cells. (D-E) Cell viability in MCF-7 parental and TamR cells bearing control ASO or ASO targeting circESR1 determined by MTT assay. (F) MCF-7 and T-47D parental and TamR cells were transiently transfected with control ASO or ASO targeting circESR1 , and were treated with different concentration gradients of CDK4/6i for 48 h. The drug killing curve of the cells was detected by MTT assay. (G) Foci formation to detect the effects of combining <t>abemaciclib,</t> palbociclib, and ribociclib on MCF-7 TamR cells transiently transfected with control ASO or ASO targeting circESR1 . (H) Immunoblot assessment of HNRNPAB, CDK1 and CDK6 proteins in MCF-7 TamR cells, which were transiently transfected with control ASO or ASO targeting circESR1 and treated with palbociclib for 48 h. (I-J) Changes in tumor growth volume in xenograft mouse models. Injected with 1×10 6 MCF-7 TamR cells under the second pair of fat pads on both sides of the mammary glands of female BALB/c nude mice (n=5/group). Tamoxifen (20 μg per dose) dissolved in 125 μL corn oil was injected every 3 days i.p. When the xenograft volume reached approximately 200 mm 3 , tumor-bearing mice were randomized and received intratumoral injection of negative control or ASO- circESR1 (5nM per dose, every 3 days) in the presence or absence of palbociclib (100mg/kg/week i.g.). (K) Hematoxylin and eosin (H&E) staining, ISH for circESR1 and IHC for Ki-67, HNRNPAB, SP1, CDK1 and CDK6 in tumor sections derived from (I). Scale bars, 20 μm. Data was shown as mean ± S.D. from three independent experiments. Unpaired two-tailed Student's t test (A-B) and two-way ANOVA test (D-E, J). ***, P < 0.001; ****, P < 0.0001.
Cdk4/6 Inhibitors In Combination With Xvir N 31, supplied by XVir Therapeutics GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cdk4/6 inhibitors in combination with xvir-n-31/product/XVir Therapeutics GmbH
Average 90 stars, based on 1 article reviews
cdk4/6 inhibitors in combination with xvir-n-31 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
cdk 4/6 inhibitors  (Innovative Therapies)
90
Innovative Therapies cdk 4/6 inhibitors
Combined treatment of antiestrogen-resistant ER+ BC with ASO targeting circESR1 and CDK4/6i. (A-B) The relative expression of circESR1 , ESR1 mRNA and ESR1 pre-mRNA in MCF-7 or T-47D parental and tamoxifen resistant (TamR) cells analyzed by qRT-PCR. (C) Immunoblot assessed the expression of HNRNPAB, SP1, CDK1, CDK6 and ERα proteins in MCF-7 parental and TamR cells. (D-E) Cell viability in MCF-7 parental and TamR cells bearing control ASO or ASO targeting circESR1 determined by MTT assay. (F) MCF-7 and T-47D parental and TamR cells were transiently transfected with control ASO or ASO targeting circESR1 , and were treated with different concentration gradients of CDK4/6i for 48 h. The drug killing curve of the cells was detected by MTT assay. (G) Foci formation to detect the effects of combining <t>abemaciclib,</t> palbociclib, and ribociclib on MCF-7 TamR cells transiently transfected with control ASO or ASO targeting circESR1 . (H) Immunoblot assessment of HNRNPAB, CDK1 and CDK6 proteins in MCF-7 TamR cells, which were transiently transfected with control ASO or ASO targeting circESR1 and treated with palbociclib for 48 h. (I-J) Changes in tumor growth volume in xenograft mouse models. Injected with 1×10 6 MCF-7 TamR cells under the second pair of fat pads on both sides of the mammary glands of female BALB/c nude mice (n=5/group). Tamoxifen (20 μg per dose) dissolved in 125 μL corn oil was injected every 3 days i.p. When the xenograft volume reached approximately 200 mm 3 , tumor-bearing mice were randomized and received intratumoral injection of negative control or ASO- circESR1 (5nM per dose, every 3 days) in the presence or absence of palbociclib (100mg/kg/week i.g.). (K) Hematoxylin and eosin (H&E) staining, ISH for circESR1 and IHC for Ki-67, HNRNPAB, SP1, CDK1 and CDK6 in tumor sections derived from (I). Scale bars, 20 μm. Data was shown as mean ± S.D. from three independent experiments. Unpaired two-tailed Student's t test (A-B) and two-way ANOVA test (D-E, J). ***, P < 0.001; ****, P < 0.0001.
Cdk 4/6 Inhibitors, supplied by Innovative Therapies, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cdk 4/6 inhibitors/product/Innovative Therapies
Average 90 stars, based on 1 article reviews
cdk 4/6 inhibitors - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
cdk4/6 inhibitor (palbociclib  (Merck & Co)
90
Merck & Co cdk4/6 inhibitor (palbociclib
Combined treatment of antiestrogen-resistant ER+ BC with ASO targeting circESR1 and CDK4/6i. (A-B) The relative expression of circESR1 , ESR1 mRNA and ESR1 pre-mRNA in MCF-7 or T-47D parental and tamoxifen resistant (TamR) cells analyzed by qRT-PCR. (C) Immunoblot assessed the expression of HNRNPAB, SP1, CDK1, CDK6 and ERα proteins in MCF-7 parental and TamR cells. (D-E) Cell viability in MCF-7 parental and TamR cells bearing control ASO or ASO targeting circESR1 determined by MTT assay. (F) MCF-7 and T-47D parental and TamR cells were transiently transfected with control ASO or ASO targeting circESR1 , and were treated with different concentration gradients of CDK4/6i for 48 h. The drug killing curve of the cells was detected by MTT assay. (G) Foci formation to detect the effects of combining <t>abemaciclib,</t> palbociclib, and ribociclib on MCF-7 TamR cells transiently transfected with control ASO or ASO targeting circESR1 . (H) Immunoblot assessment of HNRNPAB, CDK1 and CDK6 proteins in MCF-7 TamR cells, which were transiently transfected with control ASO or ASO targeting circESR1 and treated with palbociclib for 48 h. (I-J) Changes in tumor growth volume in xenograft mouse models. Injected with 1×10 6 MCF-7 TamR cells under the second pair of fat pads on both sides of the mammary glands of female BALB/c nude mice (n=5/group). Tamoxifen (20 μg per dose) dissolved in 125 μL corn oil was injected every 3 days i.p. When the xenograft volume reached approximately 200 mm 3 , tumor-bearing mice were randomized and received intratumoral injection of negative control or ASO- circESR1 (5nM per dose, every 3 days) in the presence or absence of palbociclib (100mg/kg/week i.g.). (K) Hematoxylin and eosin (H&E) staining, ISH for circESR1 and IHC for Ki-67, HNRNPAB, SP1, CDK1 and CDK6 in tumor sections derived from (I). Scale bars, 20 μm. Data was shown as mean ± S.D. from three independent experiments. Unpaired two-tailed Student's t test (A-B) and two-way ANOVA test (D-E, J). ***, P < 0.001; ****, P < 0.0001.
Cdk4/6 Inhibitor (Palbociclib, supplied by Merck & Co, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cdk4/6 inhibitor (palbociclib/product/Merck & Co
Average 90 stars, based on 1 article reviews
cdk4/6 inhibitor (palbociclib - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
cdk4/6 inhibitor  (Simcyp)
90
Simcyp cdk4/6 inhibitor
Combined treatment of antiestrogen-resistant ER+ BC with ASO targeting circESR1 and CDK4/6i. (A-B) The relative expression of circESR1 , ESR1 mRNA and ESR1 pre-mRNA in MCF-7 or T-47D parental and tamoxifen resistant (TamR) cells analyzed by qRT-PCR. (C) Immunoblot assessed the expression of HNRNPAB, SP1, CDK1, CDK6 and ERα proteins in MCF-7 parental and TamR cells. (D-E) Cell viability in MCF-7 parental and TamR cells bearing control ASO or ASO targeting circESR1 determined by MTT assay. (F) MCF-7 and T-47D parental and TamR cells were transiently transfected with control ASO or ASO targeting circESR1 , and were treated with different concentration gradients of CDK4/6i for 48 h. The drug killing curve of the cells was detected by MTT assay. (G) Foci formation to detect the effects of combining <t>abemaciclib,</t> palbociclib, and ribociclib on MCF-7 TamR cells transiently transfected with control ASO or ASO targeting circESR1 . (H) Immunoblot assessment of HNRNPAB, CDK1 and CDK6 proteins in MCF-7 TamR cells, which were transiently transfected with control ASO or ASO targeting circESR1 and treated with palbociclib for 48 h. (I-J) Changes in tumor growth volume in xenograft mouse models. Injected with 1×10 6 MCF-7 TamR cells under the second pair of fat pads on both sides of the mammary glands of female BALB/c nude mice (n=5/group). Tamoxifen (20 μg per dose) dissolved in 125 μL corn oil was injected every 3 days i.p. When the xenograft volume reached approximately 200 mm 3 , tumor-bearing mice were randomized and received intratumoral injection of negative control or ASO- circESR1 (5nM per dose, every 3 days) in the presence or absence of palbociclib (100mg/kg/week i.g.). (K) Hematoxylin and eosin (H&E) staining, ISH for circESR1 and IHC for Ki-67, HNRNPAB, SP1, CDK1 and CDK6 in tumor sections derived from (I). Scale bars, 20 μm. Data was shown as mean ± S.D. from three independent experiments. Unpaired two-tailed Student's t test (A-B) and two-way ANOVA test (D-E, J). ***, P < 0.001; ****, P < 0.0001.
Cdk4/6 Inhibitor, supplied by Simcyp, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cdk4/6 inhibitor/product/Simcyp
Average 90 stars, based on 1 article reviews
cdk4/6 inhibitor - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
cdk4/6 inhibitor palbociclib  (KU Leuven)
90
KU Leuven cdk4/6 inhibitor palbociclib
Combined treatment of antiestrogen-resistant ER+ BC with ASO targeting circESR1 and CDK4/6i. (A-B) The relative expression of circESR1 , ESR1 mRNA and ESR1 pre-mRNA in MCF-7 or T-47D parental and tamoxifen resistant (TamR) cells analyzed by qRT-PCR. (C) Immunoblot assessed the expression of HNRNPAB, SP1, CDK1, CDK6 and ERα proteins in MCF-7 parental and TamR cells. (D-E) Cell viability in MCF-7 parental and TamR cells bearing control ASO or ASO targeting circESR1 determined by MTT assay. (F) MCF-7 and T-47D parental and TamR cells were transiently transfected with control ASO or ASO targeting circESR1 , and were treated with different concentration gradients of CDK4/6i for 48 h. The drug killing curve of the cells was detected by MTT assay. (G) Foci formation to detect the effects of combining <t>abemaciclib,</t> palbociclib, and ribociclib on MCF-7 TamR cells transiently transfected with control ASO or ASO targeting circESR1 . (H) Immunoblot assessment of HNRNPAB, CDK1 and CDK6 proteins in MCF-7 TamR cells, which were transiently transfected with control ASO or ASO targeting circESR1 and treated with palbociclib for 48 h. (I-J) Changes in tumor growth volume in xenograft mouse models. Injected with 1×10 6 MCF-7 TamR cells under the second pair of fat pads on both sides of the mammary glands of female BALB/c nude mice (n=5/group). Tamoxifen (20 μg per dose) dissolved in 125 μL corn oil was injected every 3 days i.p. When the xenograft volume reached approximately 200 mm 3 , tumor-bearing mice were randomized and received intratumoral injection of negative control or ASO- circESR1 (5nM per dose, every 3 days) in the presence or absence of palbociclib (100mg/kg/week i.g.). (K) Hematoxylin and eosin (H&E) staining, ISH for circESR1 and IHC for Ki-67, HNRNPAB, SP1, CDK1 and CDK6 in tumor sections derived from (I). Scale bars, 20 μm. Data was shown as mean ± S.D. from three independent experiments. Unpaired two-tailed Student's t test (A-B) and two-way ANOVA test (D-E, J). ***, P < 0.001; ****, P < 0.0001.
Cdk4/6 Inhibitor Palbociclib, supplied by KU Leuven, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cdk4/6 inhibitor palbociclib/product/KU Leuven
Average 90 stars, based on 1 article reviews
cdk4/6 inhibitor palbociclib - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
cdk 4/6 inhibitors  (Amgen)
90
Amgen cdk 4/6 inhibitors
Combined treatment of antiestrogen-resistant ER+ BC with ASO targeting circESR1 and CDK4/6i. (A-B) The relative expression of circESR1 , ESR1 mRNA and ESR1 pre-mRNA in MCF-7 or T-47D parental and tamoxifen resistant (TamR) cells analyzed by qRT-PCR. (C) Immunoblot assessed the expression of HNRNPAB, SP1, CDK1, CDK6 and ERα proteins in MCF-7 parental and TamR cells. (D-E) Cell viability in MCF-7 parental and TamR cells bearing control ASO or ASO targeting circESR1 determined by MTT assay. (F) MCF-7 and T-47D parental and TamR cells were transiently transfected with control ASO or ASO targeting circESR1 , and were treated with different concentration gradients of CDK4/6i for 48 h. The drug killing curve of the cells was detected by MTT assay. (G) Foci formation to detect the effects of combining <t>abemaciclib,</t> palbociclib, and ribociclib on MCF-7 TamR cells transiently transfected with control ASO or ASO targeting circESR1 . (H) Immunoblot assessment of HNRNPAB, CDK1 and CDK6 proteins in MCF-7 TamR cells, which were transiently transfected with control ASO or ASO targeting circESR1 and treated with palbociclib for 48 h. (I-J) Changes in tumor growth volume in xenograft mouse models. Injected with 1×10 6 MCF-7 TamR cells under the second pair of fat pads on both sides of the mammary glands of female BALB/c nude mice (n=5/group). Tamoxifen (20 μg per dose) dissolved in 125 μL corn oil was injected every 3 days i.p. When the xenograft volume reached approximately 200 mm 3 , tumor-bearing mice were randomized and received intratumoral injection of negative control or ASO- circESR1 (5nM per dose, every 3 days) in the presence or absence of palbociclib (100mg/kg/week i.g.). (K) Hematoxylin and eosin (H&E) staining, ISH for circESR1 and IHC for Ki-67, HNRNPAB, SP1, CDK1 and CDK6 in tumor sections derived from (I). Scale bars, 20 μm. Data was shown as mean ± S.D. from three independent experiments. Unpaired two-tailed Student's t test (A-B) and two-way ANOVA test (D-E, J). ***, P < 0.001; ****, P < 0.0001.
Cdk 4/6 Inhibitors, supplied by Amgen, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cdk 4/6 inhibitors/product/Amgen
Average 90 stars, based on 1 article reviews
cdk 4/6 inhibitors - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
cdk4/6 inhibitor  (MonARC Bionetworks)
90
MonARC Bionetworks cdk4/6 inhibitor
Combined treatment of antiestrogen-resistant ER+ BC with ASO targeting circESR1 and CDK4/6i. (A-B) The relative expression of circESR1 , ESR1 mRNA and ESR1 pre-mRNA in MCF-7 or T-47D parental and tamoxifen resistant (TamR) cells analyzed by qRT-PCR. (C) Immunoblot assessed the expression of HNRNPAB, SP1, CDK1, CDK6 and ERα proteins in MCF-7 parental and TamR cells. (D-E) Cell viability in MCF-7 parental and TamR cells bearing control ASO or ASO targeting circESR1 determined by MTT assay. (F) MCF-7 and T-47D parental and TamR cells were transiently transfected with control ASO or ASO targeting circESR1 , and were treated with different concentration gradients of CDK4/6i for 48 h. The drug killing curve of the cells was detected by MTT assay. (G) Foci formation to detect the effects of combining <t>abemaciclib,</t> palbociclib, and ribociclib on MCF-7 TamR cells transiently transfected with control ASO or ASO targeting circESR1 . (H) Immunoblot assessment of HNRNPAB, CDK1 and CDK6 proteins in MCF-7 TamR cells, which were transiently transfected with control ASO or ASO targeting circESR1 and treated with palbociclib for 48 h. (I-J) Changes in tumor growth volume in xenograft mouse models. Injected with 1×10 6 MCF-7 TamR cells under the second pair of fat pads on both sides of the mammary glands of female BALB/c nude mice (n=5/group). Tamoxifen (20 μg per dose) dissolved in 125 μL corn oil was injected every 3 days i.p. When the xenograft volume reached approximately 200 mm 3 , tumor-bearing mice were randomized and received intratumoral injection of negative control or ASO- circESR1 (5nM per dose, every 3 days) in the presence or absence of palbociclib (100mg/kg/week i.g.). (K) Hematoxylin and eosin (H&E) staining, ISH for circESR1 and IHC for Ki-67, HNRNPAB, SP1, CDK1 and CDK6 in tumor sections derived from (I). Scale bars, 20 μm. Data was shown as mean ± S.D. from three independent experiments. Unpaired two-tailed Student's t test (A-B) and two-way ANOVA test (D-E, J). ***, P < 0.001; ****, P < 0.0001.
Cdk4/6 Inhibitor, supplied by MonARC Bionetworks, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cdk4/6 inhibitor/product/MonARC Bionetworks
Average 90 stars, based on 1 article reviews
cdk4/6 inhibitor - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
cdk4/6 inhibitor ribo  (Institut Curie)
90
Institut Curie cdk4/6 inhibitor ribo
Combined treatment of antiestrogen-resistant ER+ BC with ASO targeting circESR1 and CDK4/6i. (A-B) The relative expression of circESR1 , ESR1 mRNA and ESR1 pre-mRNA in MCF-7 or T-47D parental and tamoxifen resistant (TamR) cells analyzed by qRT-PCR. (C) Immunoblot assessed the expression of HNRNPAB, SP1, CDK1, CDK6 and ERα proteins in MCF-7 parental and TamR cells. (D-E) Cell viability in MCF-7 parental and TamR cells bearing control ASO or ASO targeting circESR1 determined by MTT assay. (F) MCF-7 and T-47D parental and TamR cells were transiently transfected with control ASO or ASO targeting circESR1 , and were treated with different concentration gradients of CDK4/6i for 48 h. The drug killing curve of the cells was detected by MTT assay. (G) Foci formation to detect the effects of combining <t>abemaciclib,</t> palbociclib, and ribociclib on MCF-7 TamR cells transiently transfected with control ASO or ASO targeting circESR1 . (H) Immunoblot assessment of HNRNPAB, CDK1 and CDK6 proteins in MCF-7 TamR cells, which were transiently transfected with control ASO or ASO targeting circESR1 and treated with palbociclib for 48 h. (I-J) Changes in tumor growth volume in xenograft mouse models. Injected with 1×10 6 MCF-7 TamR cells under the second pair of fat pads on both sides of the mammary glands of female BALB/c nude mice (n=5/group). Tamoxifen (20 μg per dose) dissolved in 125 μL corn oil was injected every 3 days i.p. When the xenograft volume reached approximately 200 mm 3 , tumor-bearing mice were randomized and received intratumoral injection of negative control or ASO- circESR1 (5nM per dose, every 3 days) in the presence or absence of palbociclib (100mg/kg/week i.g.). (K) Hematoxylin and eosin (H&E) staining, ISH for circESR1 and IHC for Ki-67, HNRNPAB, SP1, CDK1 and CDK6 in tumor sections derived from (I). Scale bars, 20 μm. Data was shown as mean ± S.D. from three independent experiments. Unpaired two-tailed Student's t test (A-B) and two-way ANOVA test (D-E, J). ***, P < 0.001; ****, P < 0.0001.
Cdk4/6 Inhibitor Ribo, supplied by Institut Curie, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cdk4/6 inhibitor ribo/product/Institut Curie
Average 90 stars, based on 1 article reviews
cdk4/6 inhibitor ribo - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

Image Search Results


Combined treatment of antiestrogen-resistant ER+ BC with ASO targeting circESR1 and CDK4/6i. (A-B) The relative expression of circESR1 , ESR1 mRNA and ESR1 pre-mRNA in MCF-7 or T-47D parental and tamoxifen resistant (TamR) cells analyzed by qRT-PCR. (C) Immunoblot assessed the expression of HNRNPAB, SP1, CDK1, CDK6 and ERα proteins in MCF-7 parental and TamR cells. (D-E) Cell viability in MCF-7 parental and TamR cells bearing control ASO or ASO targeting circESR1 determined by MTT assay. (F) MCF-7 and T-47D parental and TamR cells were transiently transfected with control ASO or ASO targeting circESR1 , and were treated with different concentration gradients of CDK4/6i for 48 h. The drug killing curve of the cells was detected by MTT assay. (G) Foci formation to detect the effects of combining abemaciclib, palbociclib, and ribociclib on MCF-7 TamR cells transiently transfected with control ASO or ASO targeting circESR1 . (H) Immunoblot assessment of HNRNPAB, CDK1 and CDK6 proteins in MCF-7 TamR cells, which were transiently transfected with control ASO or ASO targeting circESR1 and treated with palbociclib for 48 h. (I-J) Changes in tumor growth volume in xenograft mouse models. Injected with 1×10 6 MCF-7 TamR cells under the second pair of fat pads on both sides of the mammary glands of female BALB/c nude mice (n=5/group). Tamoxifen (20 μg per dose) dissolved in 125 μL corn oil was injected every 3 days i.p. When the xenograft volume reached approximately 200 mm 3 , tumor-bearing mice were randomized and received intratumoral injection of negative control or ASO- circESR1 (5nM per dose, every 3 days) in the presence or absence of palbociclib (100mg/kg/week i.g.). (K) Hematoxylin and eosin (H&E) staining, ISH for circESR1 and IHC for Ki-67, HNRNPAB, SP1, CDK1 and CDK6 in tumor sections derived from (I). Scale bars, 20 μm. Data was shown as mean ± S.D. from three independent experiments. Unpaired two-tailed Student's t test (A-B) and two-way ANOVA test (D-E, J). ***, P < 0.001; ****, P < 0.0001.

Journal: International Journal of Biological Sciences

Article Title: The Interaction of CircESR1 and HNRNPAB Regulates Cell Cycle Transition of Breast Cancer Cell

doi: 10.7150/ijbs.126014

Figure Lengend Snippet: Combined treatment of antiestrogen-resistant ER+ BC with ASO targeting circESR1 and CDK4/6i. (A-B) The relative expression of circESR1 , ESR1 mRNA and ESR1 pre-mRNA in MCF-7 or T-47D parental and tamoxifen resistant (TamR) cells analyzed by qRT-PCR. (C) Immunoblot assessed the expression of HNRNPAB, SP1, CDK1, CDK6 and ERα proteins in MCF-7 parental and TamR cells. (D-E) Cell viability in MCF-7 parental and TamR cells bearing control ASO or ASO targeting circESR1 determined by MTT assay. (F) MCF-7 and T-47D parental and TamR cells were transiently transfected with control ASO or ASO targeting circESR1 , and were treated with different concentration gradients of CDK4/6i for 48 h. The drug killing curve of the cells was detected by MTT assay. (G) Foci formation to detect the effects of combining abemaciclib, palbociclib, and ribociclib on MCF-7 TamR cells transiently transfected with control ASO or ASO targeting circESR1 . (H) Immunoblot assessment of HNRNPAB, CDK1 and CDK6 proteins in MCF-7 TamR cells, which were transiently transfected with control ASO or ASO targeting circESR1 and treated with palbociclib for 48 h. (I-J) Changes in tumor growth volume in xenograft mouse models. Injected with 1×10 6 MCF-7 TamR cells under the second pair of fat pads on both sides of the mammary glands of female BALB/c nude mice (n=5/group). Tamoxifen (20 μg per dose) dissolved in 125 μL corn oil was injected every 3 days i.p. When the xenograft volume reached approximately 200 mm 3 , tumor-bearing mice were randomized and received intratumoral injection of negative control or ASO- circESR1 (5nM per dose, every 3 days) in the presence or absence of palbociclib (100mg/kg/week i.g.). (K) Hematoxylin and eosin (H&E) staining, ISH for circESR1 and IHC for Ki-67, HNRNPAB, SP1, CDK1 and CDK6 in tumor sections derived from (I). Scale bars, 20 μm. Data was shown as mean ± S.D. from three independent experiments. Unpaired two-tailed Student's t test (A-B) and two-way ANOVA test (D-E, J). ***, P < 0.001; ****, P < 0.0001.

Article Snippet: Tamoxifen (T6906), Fulvestrant (T2146), Abemaciclib (T2381), Palbociclib (T1785) and Ribociclib (T6199) were from Targetmol (Boston, USA).

Techniques: Expressing, Quantitative RT-PCR, Western Blot, Control, MTT Assay, Transfection, Concentration Assay, Injection, Negative Control, Staining, Derivative Assay, Two Tailed Test